Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) was the target of unusually large options trading on Monday. Stock investors purchased 11,832 call options on the company, reports. This is an increase of 995% compared to the average daily volume of 1,081 call options.

In other Achillion Pharmaceuticals news, major shareholder Qvt Associates Gp Llc unloaded 128,649 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $7.66, for a total transaction of $985,451.34. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Several analysts have recently commented on the stock. Analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $12.00 price target on the stock, up previously from $4.00. Finally, analysts at Deutsche Bank raised their price target on shares of Achillion Pharmaceuticals to $6.00 in a research note on Tuesday, June 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.71.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 20.87% on Monday, hitting $7.82. 35,420,216 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $8.49. The stock has a 50-day moving average of $3.29 and a 200-day moving average of $3.34. The company’s market cap is $756.9 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.01. Analysts expect that Achillion Pharmaceuticals will post $-0.77 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.